Pharmafile Logo
Pharmafocus logo
Advanced Search

immuno-oncology

Showing 15 posts of 36 posts found.

rd_hands

Japan’s Ono Pharma focusing on building immuno-oncology portfolio with Opdivo

March 7, 2016
Sales and Marketing Bristol-Myers Sqibb, Ono Pharma, immuno-oncology, opdivo

Japan’s Ono Pharmaceutical has said it is focused on building on its immuno-oncology portfolio following the success of its PD-1 …

News
AbbVie

AbbVie and MD Anderson in cancer research partnership

January 25, 2016
Research and Development, Sales and Marketing AbbVie, MD Anderson Cancer Centre, immuno-oncology

AbbVie has announced a new partnership with The University of Texas MD Anderson Cancer Centre, using its immunotherapy platform to …

News
MSD logo

MSD to acquire Scottish firm IOmet Pharma

January 12, 2016
Research and Development, Sales and Marketing IOMet Pharma, MSD, Merck, Scotland, acquisitions, immuno-oncology, mergers, oncology

US pharma company MSD is to buy Edinburgh based IOMet Pharma to expand its existing R&D programme, exploring the development …

News
Elias Zerhouni

Sanofi seals double oncology research deals

January 11, 2016
Research and Development, Sales and Marketing Sanofi, Warp Drive Bio, antibodies, collaboration, immuno-oncology, research

Sanofi has signed two separate research agreements for €1.2 billion, which will give the French firm licensing rights to potential …

News
novartis_window

Novartis expands immuno-oncology programme

January 11, 2016
Research and Development, Sales and Marketing Cancer, Novartis, Surface Oncology, collaboration, immuno-oncology

Novartis has further bolstered its immuno-oncology pipeline through a strategic alliance and licensing agreement with Surface Oncology, as it moves …

News
dr_paolo_paoletti

PsiOxus Therapeutics appoints Dr Paolo Paoletti as chairman of the board

January 7, 2016
Manufacturing and Production, Medical Communications, Research and Development Cancer, Dr Paolo Paoletti, GSK, PsiOxus Therapeutics, immuno-oncology, oncology

Immuno-oncology company PsiOxus Therapeutics has appointed Kesios Therapeutics chief executive, and former president of GSK Oncology, Dr Paolo Paoletti, as chairman …

Appointment
Janssen image

Janssen, Enterome and Kymab in research collaborations

January 7, 2016
Research and Development Crohn's, Crohn’s disease, Enterome, Janssen, MD Anderson, alliance, antibodies, collaboration, crohn's disease, immuno-oncology, kymab, research

Several pharma companies have announced new collaborations, to research potential new drugs for Crohn’s disease, and immuno-oncology treatments for cancer. …

News
BMS

Bristol-Myers Squibb in new oncology collaboration

November 25, 2015
Research and Development Bristol-Myers Squibb, collaboration, immuno-oncology, investment, venture capital

Bristol-Myers Squibb and European healthcare fund Life Sciences Partners are forming a strategic collaboration to identify breakthrough technologies.  The companies …

News
T-cell

$350m collaboration deal for BMS and Five Prime Therapeutics

October 15, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

News
Ablynx flags

Ablynx and Merck begin immuno-oncology collaboration

October 15, 2015
Research and Development Ablynx, Merck, immuno-oncology, nanobody, proof of concept

Ablynx has achieved a pre-clinical proof-of-concept with a nanobody construct as part of its immuno-oncology collaboration with Merck – triggering …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

News
R&D

Sanofi, Evotec and Apeiron partner on immuno-oncology

August 10, 2015
Research and Development, Sales and Marketing Apeiron, Cancer, Evotec, Sanofi, immuno-oncology, immunotherapy, tumours

Sanofi is partnering with biotech companies Evotec and Apeiron to develop new cancer immuno-oncology therapies.The companies say the potential new …

News
MedImmune building Cambridge

MedImmune and Mirati to partner on lung cancer combo

August 6, 2015
Research and Development AstraZeneca, Cancer, MedImmune, Mirati, Mirati Therapeutics, NSCLC, durvalumab, immuno-oncology, immunotherapy, lung cancer, mocetinostat

MedImmune is entering into an exclusive clinical trial collaboration with US-based Mirati Therapeutics to test a novel immuno-oncology combination in …

News
astrazeneca image

AstraZeneca buys rights to Heptares experimental cancer treatment

August 6, 2015
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Cancer, HTL-1071, immuno-oncology

AstraZeneca has entered into a licensing agreement with Heptares for the global rights to the experimental cancer treatment HTL-1071. The …

News

Latest content

AbbVie invests €150m in new R&D facility in Germany

May 3, 2024

AstraZeneca shares positive interim results from phase 3 lymphoma trial

May 3, 2024

Merck shares data from phase 3 trial of Keytruda for gastric cancers

May 2, 2024

Verona Pharma to share phase 3 COPD trial data at ATS 2024

May 2, 2024

Beckman Coulter Life Sciences and Watchmaker Genomics enter collaboration

May 1, 2024